Category Archives: "INforMS"

TG Therapeutics, Inc. announces final phase 2 multiple sclerosis data presentation at ECTRIMS
Annualized Relapse Rate (ARR) of 0.07 observed for all patients on Phase 2 trial ECTRIMS data review conference call to be held [...]
Novartis announces FDA filing acceptance of Siponimod (BAF312)
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS), a highly debilitating [...]
New efficacy and safety data on multiple sclerosis portfolio to be presented
​Late-breaking Phase II primary endpoint data for investigational therapy evobrutinib, the first oral BTK inhibitor to show [...]
Press release – Ocrevus data show early initiation reduces progression
Dear Advocates, OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression over Five Years in [...]
Novartis announces PARADIGMS study demonstrating benefit of Gilenya®
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents [...]
Researchers identify new subtype of multiple sclerosis
Researchers have discovered a new subtype of multiple sclerosis (MS), providing a better understanding of the disease and potentially [...]
MRI tests may help doctors predict multiple sclerosis progression in patients
Researchers have apparently found a way to help predict multiple sclerosis disease progression one year after an initial [...]
Researchers have a new theory about what may cause multiple sclerosis
When the following headline in the Australian newspaper the Herald Sun caught my eye recently, I was cautiously intrigued: “Doctors [...]
FDA accepts file for Cladribine tablets as potential treatment for relapsing forms of multiple sclerosis
PDF ROCKLAND, Mass., July 30, 2018 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and [...]
Temperament can play a big role in quality of life with multiple sclerosis
Researchers say if a person with multiple sclerosis is irritable or anxious, it can make overcoming the obstacles of their disease much [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us
I have a question about
First
Last